Why the study?
Additional research was needed to evaluate the effects, safety, and effectiveness of edoxaban in routine clinical practice in patients with nonvalvular AF or VTE.
What are the safety and effectiveness outcomes of edoxaban in routine clinical practice for patients with AF or VTE?
What are the safety and effectiveness outcomes of edoxaban in routine clinical practice for patients with AF or VTE?
The ETNA program will provide large-scale, prospective, real-world data on the safety and effectiveness of edoxaban in patients with AF or VTE.
Answers are grounded in this paper and cite their sources.
Supports edoxaban safety in routine AF practice with low event rates; extends RCT data to unselected patients but leaves practice change open.
BACKGROUND: Randomized controlled trials showed the nonvitamin K oral anticoagulant (NOAC) edoxaban was effective and safe for stroke and systemic embolism prevention in nonvalvular atrial fibrillation (AF) and for the prevention and treatment of venous thromboembolism (VTE; including pulmonary embolism and deep vein thrombosis). Additional research is needed to evaluate the effects of edoxaban in routine clinical practice. Therefore, the Edoxaban Treatment in routine cliNical prActice (ETNA) program is being conducted to provide routine clinical care data on characteristics and outcomes in patients with AF or VTE receiving edoxaban. METHODS: The Global ETNA program integrates prospectively collected data from edoxaban patients in regional ETNA noninterventional studies across Europe, Japan, and East and Southeast Asia into indication-specific databases for AF and VTE. Targeted enrollment is >31 000 patients (AF >26 000; VTE >4500), with a follow-up of 2 years for AF and 1 year for VTE. Data integration will be possible using consistent terminology, parameter definitions, and data collection across the regional noninterventional studies. Safety and effectiveness data will be assessed. Crude rates of outcomes including bleeding and thromboembolic events will be reported. RESULTS: Globally, enrollment began in early 2015 and is ongoing. CONCLUSIONS: Global ETNA will generate the largest integrated prospective repository of routine clinical care data for a single NOAC in patients with AF or VTE. It will provide important information on the safety of edoxaban in routine clinical care and gather further information on its effectiveness.
No takes yet. Share an insight, caveat, or question.
Caterina et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: